| CVX |
Report |
Adjusted EPS |
BEAT |
pred ~$5.72 vs. cons $5.45 |
MEDIUM |
| CVX |
Report |
CFFO excluding working capital |
BEAT |
pred ~$18.6B vs. cons $17.8B |
MEDIUM |
| CVX |
Report |
Worldwide net oil-equivalent production |
IN-LINE |
pred ~4.03 MMboe/d vs. cons 4.00 MMboe/d |
MEDIUM |
| CVX |
Guide |
Production growth |
LOWER |
guide ~8.5% vs. cons 8.8% (FY2026) |
MEDIUM |
| CVX |
Guide |
Capital expenditures |
BETTER |
guide ~$18.5B vs. cons $18.6B (FY2026) |
HIGH |
| CVX |
Guide |
Share repurchases |
UNCHANGED |
guide ~$2.75B vs. cons $2.75B (3Q2026) |
HIGH |
| CVX |
Guide |
Structural cost reductions |
UNCHANGED |
guide ~$3.5B vs. cons $3.5B (year-end 2026 run-rate) |
MEDIUM |
| CVX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.7% |
— |
MEDIUM |
| CVX |
Return |
5-day cumulative residual |
+0.6% (FADE) |
A cash-flow-led beat should drive the initial gain, but largely unchanged operating guidance, a production-growth midpoint slightly below consensus, and lower normalized oil-price assumptions embedded in 2027 estimates should limit upward revisions and partially reverse the day-1 move. |
MEDIUM |